Haemonetics Corporation (HAE)
| Market Cap | 6.14B |
| Revenue (ttm) | 902.53M |
| Net Income (ttm) | 106.15M |
| Shares Out | 50.70M |
| EPS (ttm) | 2.07 |
| PE Ratio | 54.94 |
| Forward PE | 36.10 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 27 |
| Last Price | $113.84 |
| Previous Close | $119.12 |
| Change ($) | -5.28 |
| Change (%) | -4.43% |
| Day's Open | 117.07 |
| Day's Range | 112.99 - 117.82 |
| Day's Volume | 224,550 |
| 52-Week Range | 74.34 - 129.03 |
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON, Jan. 22, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) ("Haemonetics"), a global medical technology company focused on delivering innovative medical solutions to drive bette...
BOSTON, Jan. 20, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) ("Haemonetics"), a global medical technology company focused on delivering innovative medical solutions to drive bette...
Haemonetics (HAE) is optimistic about maintaining a robust product portfolio amid the pandemic-led business disruptions.
BOSTON, Jan. 5, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2021 financial results at 6:00 am EDT on Tuesda...
With the Covid vaccine rollout accelerating, these companies will be big beneficiaries in the year ahead.
Haemonetics has sustainable growth levers in place that are underscored by key product offerings and recent liquidity preservation measures. The company remains insulated from larger names via...
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?
We believe that Haemonetics stock, best known for its blood and plasma supplies and services, is a good buying opportunity at the present time. HAE stock trades near $113 currently and it is, ...
Haemonetics (HAE) invests in clinical trials that build evidence for its hemostasis management products.
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking ...
Haemonetics' (HAE) second-quarter fiscal 2021 results reflect impressive performance by Hospital segment despite dismal overall performance during the coronavirus-led crisis.
Haemonetics Corporation (HAE) CEO Chris Simon on Q2 2021 Results - Earnings Call Transcript
Haemonetics (HAE) delivered earnings and revenue surprises of 24.00% and 3.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Haemonetics (NYSE:HAE) fell 0.1% in pre-market trading after the company reported Q2 results.
BOSTON, Nov. 4, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its second quarter fiscal 2021, which ended September 26, 2020, are available on it...
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON, Oct. 6, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2021 financial results at 6:00 am EDT on Wednes...
BOSTON, Oct. 2, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outc...
With the third quarter of what has proven to be a remarkable 2020 coming to a close, many of the firms we cover across Wall Street already are looking to the stretch run of the year and at wha...
BOSTON, Sept. 9, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 18th Annual Morgan Stanley Virtual Global Healthcar...
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?
Shares of plasma provider Haemonetics off highs as Needham says COVID-19 EUA not material to results
Shares of blood transfusion and plasma provider Haemonetics Inc. HAE, +2.34% were off their highs on Monday, after Needham analysts said news of an emergency use authorization for convalescent...
Haemonetics Corporation (HAE) CEO Chris Simon on Q1 2020 Results - Earnings Call Transcript
BOSTON, Aug. 7, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outc...
Haemonetics' (HAE) first-quarter fiscal 2021 results reflect impressive performance by Blood Center segment despite dismal overall performance during the coronavirus-led crisis.
Haemonetics (HAE) delivered earnings and revenue surprises of 12.20% and 1.35%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Haemonetics (NYSE:HAE) moved higher by 0.1% in pre-market trading after the company reported Q1 results.
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON, July 24, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient out...
Increasingly, the Wall Street firms we cover agree that while the future is still bright for the U.S.
BOSTON, July 6, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish first quarter fiscal year 2021 financial results at 6:00 am EDT on Tuesday...
BOSTON, June 30, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient out...
With the first half of what has proven to be a remarkable 2020 coming to a close, many of the firms we cover across Wall Street already are looking to the second half of the year, with what sh...
Investors continue to be optimistic about Haemonetics (HAE) on sustained underlying product demand and geographical expansion.
Haemonetics (HAE) inks deal to enhance operations and provide high quality products through an asset-lite approach in its blood filters operations.
BOSTON, June 3, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outc...
Boston Scientific, best known for its products in interventional medical specialties, has seen its stock price grow roughly 50% in the last few years. In comparison, Haemonetics, one of the wo...
BOSTON, May 28, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outc...
Haemonetics's (HAE) CEO Chris Simon on Q4 2020 Results - Earnings Call Transcript
Haemonetics' (HAE) fourth-quarter fiscal 2020 results reflect strong performance by Plasma segment despite dismal overall performance during the coronavirus-led crisis.
Haemonetics (HAE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Haemonetics (HAE) expands its portfolio with the buyout of enicor. With the latter's whole blood coagulation testing system, the company will address a wider range of criticalities in medicine.
Haemonetics (HAE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?
Haemonetics (HAE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Haemonetics (HAE) witnesses high investor confidence on solid prospects.
About HAE
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides au... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date May 9, 1991 |
| CEO Christopher Simon | Employees 3,004 |
| Stock Exchange NYSE | Ticker Symbol HAE |
Financial Performance
In 2019, Haemonetics's revenue was $988.48 million, an increase of 2.16% compared to the previous year's $967.58 million. Earnings were $76.53 million, an increase of 39.09%.
Analyst Forecasts
According to 7 analysts, the average rating for Haemonetics stock is "Buy." The 12-month stock price forecast is 142.67, which is an increase of 25.33% from the latest price.